FDA greenlights Pfizer’s pneumococcal vaccine in infants and children
FDA greenlights Pfizer’s pneumococcal vaccine in infants and children
FDA greenlights Pfizer’s pneumococcal vaccine in infants and children
Published: Apr 28, 2023
By Tristan Manalac
BioSpace
The FDA has approved Pfizer’s Prevnar 20 (20-valent Pneumococcal Conjugate Vaccine) for use in infants and children from six weeks to 17 years of age, the company announced Thursday.
Prevnar 20 can now be used to prevent invasive pneumococcal disease (IPD) as caused by the 20 serotypes of Streptococcus pneumoniae contained in the vaccine in these pediatric patients. Children aged 6 weeks through 5 years can also receive the shot for the prevention of otitis media caused by seven of the 20 serotypes.
Prevnar 20’s approval introduces an expanded vaccine option to provide children “with the broadest serotype protection,” providing immunity against 20 serotypes, including those associated with heavy disease burden in children younger than five years, Sheldon Kaplan, chief, Division of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, said in a statement.
Moreover, Prevnar 20 “builds on more than 20 years of real-world impact with PREVNAR and PREVNAR 13,” Annaliesa Anderson, senior vice president and chief scientific officer, Vaccine Research and Development, Pfizer, added.
The FDA licensed Prevnar, Pfizer’s first pneumococcal vaccine, in 2000, and it contained seven S. pneumoniae serotypes. The same year, the seven-valent vaccine was rolled out in children and was found to be highly effective against IPD caused by these seven bacterial serotypes.
The company expanded this seven-serotype coverage in 2010, when it won FDA approval for Prevnar 13, which provided protection against IPD in young children, as caused by 13 S. pneumoniae types.
A Strong Evidence Base
Pfizer supported the supplemental Biologics License Application (sBLA) for Prevnar 20, which the FDA accepted and granted Priority Review in January, with data from a proof-of-concept Phase II study and several Phase III pediatric trials.
In October 2020, the company posted positive data from the Phase II study, showing that the 20-serotype vaccine was just as safe as its 13-serotype version, which had previously been approved in 2016. Immunogenicity analysis showed that the investigational vaccine elicited immune responses against all 20 serotypes after the third dose.
In August 2022, topline data from a pivotal Phase III study in the U.S. revealed that a four-dose series of the investigational 20-valent vaccine led to robust immunity against all serotypes with a favorable safety and tolerability profile. These findings were confirmed a month later with data from a similar study conducted in the European Union.
Tristan Manalac is an independent science writer based in metro Manila, Philippines. He can be reached at [email protected] or [email protected]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: